John Gutheil

5.5k total citations · 2 hit papers
40 papers, 4.2k citations indexed

About

John Gutheil is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, John Gutheil has authored 40 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in John Gutheil's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Glycosylation and Glycoproteins Research (5 papers). John Gutheil is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Glycosylation and Glycoproteins Research (5 papers). John Gutheil collaborates with scholars based in United States, New Zealand and Taiwan. John Gutheil's co-authors include Debu Tripathy, Charles L. Vogel, Melody Cobleigh, Louis Fehrenbacher, Lyndsay N. Harris, William Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart and Dennis J. Slamon and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

John Gutheil

39 papers receiving 4.0k citations

Hit Papers

Efficacy and Safety of Trastuzumab as a Single Agent in F... 2001 2026 2009 2017 2002 2001 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
    2002 1.5k citations Charles L. Vogel, Melody Cobleigh et al. Journal of Clinical Oncology profile →
  2. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
    2001 507 citations Gerald Batist, Gopal Ramakrishnan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Gutheil United States 17 2.3k 1.2k 1.1k 820 635 40 4.2k
Thomas M. Cardillo United States 38 2.4k 1.0× 2.0k 1.6× 1.3k 1.2× 495 0.6× 376 0.6× 94 4.1k
Kirsten B. Goldberg United States 39 2.7k 1.2× 384 0.3× 979 0.9× 1.3k 1.6× 349 0.5× 66 4.5k
R. Katherine Alpaugh United States 37 2.6k 1.1× 996 0.8× 1.7k 1.5× 444 0.5× 291 0.5× 112 4.5k
Christian Dittrich Austria 33 1.6k 0.7× 328 0.3× 1.4k 1.3× 833 1.0× 299 0.5× 136 4.0k
Víctor Moreno Spain 35 3.8k 1.6× 664 0.5× 1.8k 1.6× 1.2k 1.4× 520 0.8× 287 5.5k
Silvana Del Vecchio Italy 33 1.4k 0.6× 1.1k 0.9× 1.3k 1.1× 583 0.7× 190 0.3× 128 3.8k
Irene Kuter United States 24 3.4k 1.5× 1.3k 1.1× 513 0.5× 1.5k 1.8× 351 0.6× 45 5.3k
Richard A. Messmann United States 21 1.2k 0.5× 1.3k 1.1× 976 0.9× 1.4k 1.7× 228 0.4× 49 3.2k
Andrea Rocca Italy 33 2.3k 1.0× 413 0.3× 1.1k 1.0× 911 1.1× 488 0.8× 135 4.1k
Emiliano Cocco United States 32 1.6k 0.7× 305 0.2× 1.1k 1.0× 833 1.0× 442 0.7× 83 3.2k

Countries citing papers authored by John Gutheil

Since Specialization
Citations

This map shows the geographic impact of John Gutheil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Gutheil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Gutheil more than expected).

Fields of papers citing papers by John Gutheil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Gutheil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Gutheil. The network helps show where John Gutheil may publish in the future.

Co-authorship network of co-authors of John Gutheil

This figure shows the co-authorship network connecting the top 25 collaborators of John Gutheil. A scholar is included among the top collaborators of John Gutheil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Gutheil. John Gutheil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Yi‐Hsiang, Kun‐Yun Yeh, Pei‐Jer Chen, et al.. (2024). CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.. Journal of Clinical Oncology. 42(23_suppl). 92–92. 1 indexed citations
2.
Huang, Yi‐Hsiang, Kun‐Yun Yeh, Pei‐Jer Chen, et al.. (2024). CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.. Journal of Clinical Oncology. 42(16_suppl). e16150–e16150. 1 indexed citations
3.
Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2023). Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 41(9). 1638–1645. 16 indexed citations
4.
Su, Wu‐Chou, Li‐Yuan Bai, Jen‐Shi Chen, et al.. (2023). CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study.. Journal of Clinical Oncology. 41(16_suppl). e16235–e16235. 3 indexed citations
5.
Packiam, Vignesh T., Daniel A. Barocas, Karim Chamie, et al.. (2019). MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL. The Journal of Urology. 201(Supplement 4). 12 indexed citations
6.
Porcu, Pierluigi, Elizabeth Brém, Tatyana Feldman, et al.. (2019). A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.. Journal of Clinical Oncology. 37(15_suppl). 7551–7551. 3 indexed citations
7.
Lohrmann, Christian, Joseph A. O’Donoghue, Erkut Borazanci, et al.. (2018). Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies. Cancer Research. 78(13_Supplement). CT140–CT140. 5 indexed citations
8.
Packiam, Vignesh T., Donald L. Lamm, Daniel A. Barocas, et al.. (2017). An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results. Urologic Oncology Seminars and Original Investigations. 36(10). 440–447. 190 indexed citations
9.
Tolcher, Anthony W., Wu‐Chou Su, Nehal J. Lakhani, et al.. (2017). Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers.. Journal of Clinical Oncology. 35(15_suppl). 2580–2580. 2 indexed citations
10.
Konopleva, Marina, Gautam Borthakur, Peter F. Thall, et al.. (2011). Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection. Blood. 118(21). 1523–1523. 2 indexed citations
11.
Abou‐Alfa, Ghassan K., Stephen L. Chan, Chia‐Chi Lin, et al.. (2011). PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology. 68(2). 539–545. 24 indexed citations
12.
Jameson, Michael B., Danny Rischin, Mark D. Pegram, et al.. (2009). A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 65(4). 791–801. 68 indexed citations
13.
Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2002). Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 20(3). 719–726. 1508 indexed citations breakdown →
14.
Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2001). First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer. Oncology. 61(Suppl. 2). 37–42. 145 indexed citations
15.
Batist, Gerald, Gopal Ramakrishnan, John Gutheil, et al.. (2001). Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer. Journal of Clinical Oncology. 19(5). 1444–1454. 507 indexed citations breakdown →
16.
Stopeck, Alison, Evan M. Hersh, John A. Thompson, et al.. (2001). Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.. PubMed. 7(8). 2285–91. 90 indexed citations
17.
Zuhowski, Eleanor G., John Gutheil, & Merrill J. Egorin. (1994). Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum. Journal of Chromatography B Biomedical Sciences and Applications. 655(1). 147–152. 5 indexed citations
18.
Abrams, Jeffrey S., John Gutheil, & Joseph Aisner. (1992). Potential Applications of High-Dose Megestrol Acetate in Breast Cancer. Oncology. 49(2). 12–17. 1 indexed citations
19.
Mane, Shrikant, et al.. (1990). RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and dna base sequence determination. Genes Chromosomes and Cancer. 2(1). 71–77. 10 indexed citations
20.
Gutheil, John, et al.. (1989). Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogene product p21. Human Pathology. 20(12). 1176–1180. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas M. Cardillo Breakdown of academic impact, for papers by Kirsten B. Goldberg Breakdown of academic impact, for papers by R. Katherine Alpaugh Breakdown of academic impact, for papers by Christian Dittrich Breakdown of academic impact, for papers by Víctor Moreno Breakdown of academic impact, for papers by Silvana Del Vecchio Breakdown of academic impact, for papers by Irene Kuter Breakdown of academic impact, for papers by Richard A. Messmann Breakdown of academic impact, for papers by Andrea Rocca Breakdown of academic impact, for papers by Emiliano Cocco
Rankless by CCL
2026